Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAPN1 | P07384 | 2/20 | 0.67 |
| ▸ | CTSK | P43235 | 7/20 | 0.64 |
| ▸ | CTSL | P07711 | 8/20 | 0.62 |
| ▸ | CTSS | P25774 | 3/20 | 0.62 |
| ▸ | CTSB | P07858 | 6/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27809377 | 0.91 | CAPN1 (0.78) | CAPN1CTSKCTSLCTSSCTSB | |
| SCHEMBL7327426 | 0.91 | CAPN1 (0.78) | CAPN1CTSKCTSLCTSSCTSB | |
| SCHEMBL9828791 | 0.91 | CAPN1 (0.78) | CAPN1CTSKCTSLCTSSCTSB | |
| SCHEMBL14148469 | 0.89 | CAPN1 (0.72) | CAPN1CTSKCTSLCTSSCTSB | |
| SCHEMBL6482122 | 0.89 | CAPN1 (0.72) | CAPN1CTSKCTSLCTSSCTSB | |
| SCHEMBL6276287 | 0.89 | CAPN1 (0.72) | CAPN1CTSKCTSLCTSSCTSB | |
| SCHEMBL9825830 | 0.89 | TYR (0.58) | CTSKCTSLCTSSCTSB | |
| SCHEMBL5288135 | 0.89 | TYR (0.58) | CTSKCTSLCTSSCTSB | |
| SCHEMBL2256235 | 0.88 | CAPN1 (0.74) | CAPN1CTSKCTSLCTSSCTSB | |
| Carbon Dioxide SCHEMBL2245710 | 0.88 | CAPN1 (0.74) | CAPN1CTSKCTSLCTSSCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2004670-B1 | PROCESS FOR THE MANUFACTURE OF LYSOBACTIN DERIVATIVES | AICURIS GMBH & CO KG (DE) | 2010-01-27 | — | — | EP | disclosed |
| US-20090163696-A1 | METHOD FOR PREPARING LYSOBACTIN DERIVATIVES | BAYER HEALTHCARE AG (DE) | 2009-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163696-A1 | METHOD FOR PREPARING LYSOBACTIN DERIVATIVES | DLST, VIP, HAMP | CAPN1 1494/4885CTSK 571/4885CTSL 142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.